Phase II Trial of RAD001 in Refractory Colorectal Cancer
Basic Trial Information
|Phase II||Treatment||Completed||18 and over||Other||CRAD0012467|
Swedish Cancer Institute 05128, NCT00337545
Single center open-label study of an oral agent (RAD001) in subjects with metastatic colorectal cancer refractory to at least 2 standard chemo/biologic regimens.
Further Study Information
Study is completed and closed.
- Metastatic colorectal cancer refractory to at least 2 chemo/biologic regimens
- Measurable disease
- ECOG 0-2
- CNS disease
- Chemotherapy or radiotherapy < 4 weeks prior
- Active bleeding diathesis
Trial Contact Information
Trial Lead Organizations/Sponsors
Swedish Cancer Institute at Swedish Medical Center - First Hill Campus
- Novartis Pharmaceuticals Corporation
Link to the current ClinicalTrials.gov record.
NLM Identifier NCT00337545
ClinicalTrials.gov processed this data on February 27, 2015
Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should be directed to ClinicalTrials.gov.